Discover how researchers reconstitute and dose NAD+. Real dosage trends, vial sizes, and BAC water volumes from WPA peptide calculator data.
NAD+ reconstitution ranges widely by dose target and administration route—subcutaneous, intramuscular, or IV push. This data captures the dose amounts, vial sizes, and diluent volumes most commonly selected in the WPA calculator, providing a real-world reference for NAD+ mixing protocols.
NAD+ — nicotinamide adenine dinucleotide — is the central electron-shuttling cofactor of cellular energy metabolism, and the supplementation literature around it is one of the deeper ones in modern longevity science. The molecular logic that drives interest in NAD+ supplementation traces to two converging research lines. The Charles Brenner group at the University of Iowa identified nicotinamide riboside (NR) as an NAD+ precursor in 2004 and went on to seed the clinical NR program at ChromaDex (the Niagen brand). The Shin-ichiro Imai group at Washington University and the David Sinclair group at Harvard developed the nicotinamide mononucleotide (NMN) precursor literature, characterizing NMN's effects on age-related metabolic decline, sirtuin activation, and mitochondrial function in mouse models. The downstream human supplementation literature — Dollerup et al.
NAD+ is the cellular coenzyme most often sourced for longevity, metabolic, and recovery research, used directly via IV/IM or through precursors like NMN and NR. Injectable research material ships as a lyophilized powder reconstituted with bacteriostatic water before use.
As an electron carrier NAD+ shuttles reducing equivalents through the citric-acid cycle and oxidative phosphorylation. As a substrate it is consumed by sirtuins during deacetylation, by PARP enzymes during DNA-damage repair, and by CD38 during cyclic-ADP-ribose signalling. Replenishing the NAD+ pool is hypothesized to restore mitochondrial function and DNA-repair capacity in aged cells.
Human trials have focused on NAD+ precursors (NR, NMN) rather than direct NAD+ administration; randomized work in Parkinson disease (NR-SAFE, Brakedal et al., Cell Metab 2022) showed cerebral NAD elevation and modest clinical signal. Direct intravenous NAD+ remains under-studied in controlled trials, with most published work limited to addiction-recovery protocols and small open-label series.
NAD+ has a reported half-life of ~30 min (serum), and the dose intervals researchers model most often fall around weekly. Serum NAD+ clears almost completely between weekly doses, so there is essentially no plasma buildup. The benefit tracks intracellular precursor pools rather than a steady-state blood level. It is catalogued under Anti-Aging Peptides on WPA.
10,778 NAD+ reconstitution calculations have been logged by the WPA community. The most common dose entered is 50mg (2,702 calculations). The median dose across all sessions is 30mg. The most common bacteriostatic water volume is 5mL. The most popular vial size is 500mg (6,927 sessions). The most common dosing frequency is once weekly (927 logged protocols), followed by 2x/week (875).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.